Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
NEPHROLOGY / EXPERIMENTAL RESEARCH
Therapeutic potential of mesenchymal stem cells in cisplatin-induced acute kidney injury via ASK-1/TXNIP pathway modulation
1
Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, October University for Modern Sciences and Arts, October, Egypt
2
Department of Pharmacology, Faculty of Pharmacy, October University for Modern Sciences and Arts, October, Egypt
Submission date: 2024-04-24
Final revision date: 2024-09-02
Acceptance date: 2024-09-25
Online publication date: 2024-11-02
Corresponding author
Sherine M. Ibrahim
Department of Biochemistry and Molecular Biology Faculty of Pharmacy, October University for Modern Sciences and Arts, October, Egypt
Department of Biochemistry and Molecular Biology Faculty of Pharmacy, October University for Modern Sciences and Arts, October, Egypt
KEYWORDS
acute kidney injurymesenchymal stem cellsanti-inflammatoryanti-apoptoticapoptosis signal-regulating kinase 1thioredoxin-interacting proteinvascular endothelial growth factor
TOPICS
ABSTRACT
Introduction:
Acute kidney injury (AKI) is a diverse set of illnesses characterized by a rapid decline in kidney function. However, kidney transplantation and supportive therapies still have many limitations in slowing the progression of kidney diseases. The effective role of mesenchymal stem cells (MSCs) in cell-based therapy and endogenous repair for AKI is still under investigation. Several studies have indicated that MSCs could both repair and ameliorate kidney injury due to its anti-inflammatory and anti-apoptotic potential effects. The aim of this study was to evaluate the effects of MSCs on renal cell apoptosis in cisplatin-induced AKI rats and examine the underlying molecular mechanisms.
Material and methods:
Characteristics and homing of MSCs to kidney tissues were identified by flow cytometry and differentiation capability. After AKI induction by cisplatin injection in sixteen albino rats, the AKI rats were further subdivided into three subgroups. The first subgroup served as a positive control and the second one received 2 mg/kg furosemide (FUR), which served as a standard drug. The third subgroup received a single dose of 5 × 106 MSCs via tail vein injection once a week for 2 consecutive weeks. AKI-related biochemical parameters were assayed at 2 weeks after MSC treatment. Kidney histological changes were also evaluated. Moreover, apoptosis of kidney cells and expression of apoptosis-related proteins were assessed by western blot.
Results:
Compared with AKI rats, rats treated with MSCs showed suppressed serum levels of creatinine and blood urea nitrogen. MSC treatment alleviated the pathological abnormalities in the kidneys of AKI rats as shown by H&E staining. Furthermore, MSC treatment suppressed apoptosis of kidney cells in AKI rats via downregulation of apoptotic proteins: thioredoxin-interacting protein (TXNIP) and apoptosis signal-regulating kinase 1 (ASK1). Most importantly, MSC treatment promoted the expression of vascular endothelial growth factor (VEGF) in the kidneys of AKI rats.
Conclusions:
Our results suggest that MSCs could ameliorate renal injury of AKI rats via their anti-apoptotic properties. Also, the protective effects of MSCs may be mediated by their potential angiogenic effects.
Acute kidney injury (AKI) is a diverse set of illnesses characterized by a rapid decline in kidney function. However, kidney transplantation and supportive therapies still have many limitations in slowing the progression of kidney diseases. The effective role of mesenchymal stem cells (MSCs) in cell-based therapy and endogenous repair for AKI is still under investigation. Several studies have indicated that MSCs could both repair and ameliorate kidney injury due to its anti-inflammatory and anti-apoptotic potential effects. The aim of this study was to evaluate the effects of MSCs on renal cell apoptosis in cisplatin-induced AKI rats and examine the underlying molecular mechanisms.
Material and methods:
Characteristics and homing of MSCs to kidney tissues were identified by flow cytometry and differentiation capability. After AKI induction by cisplatin injection in sixteen albino rats, the AKI rats were further subdivided into three subgroups. The first subgroup served as a positive control and the second one received 2 mg/kg furosemide (FUR), which served as a standard drug. The third subgroup received a single dose of 5 × 106 MSCs via tail vein injection once a week for 2 consecutive weeks. AKI-related biochemical parameters were assayed at 2 weeks after MSC treatment. Kidney histological changes were also evaluated. Moreover, apoptosis of kidney cells and expression of apoptosis-related proteins were assessed by western blot.
Results:
Compared with AKI rats, rats treated with MSCs showed suppressed serum levels of creatinine and blood urea nitrogen. MSC treatment alleviated the pathological abnormalities in the kidneys of AKI rats as shown by H&E staining. Furthermore, MSC treatment suppressed apoptosis of kidney cells in AKI rats via downregulation of apoptotic proteins: thioredoxin-interacting protein (TXNIP) and apoptosis signal-regulating kinase 1 (ASK1). Most importantly, MSC treatment promoted the expression of vascular endothelial growth factor (VEGF) in the kidneys of AKI rats.
Conclusions:
Our results suggest that MSCs could ameliorate renal injury of AKI rats via their anti-apoptotic properties. Also, the protective effects of MSCs may be mediated by their potential angiogenic effects.
REFERENCES (66)
1.
Nagata K, Horino T, Hatakeyama Y, Matsumoto T, Terada Y, Okuhara Y. Effects of transient acute kidney injury, persistent acute kidney injury and acute kidney disease on the long-term renal prognosis after an initial acute kidney injury event. Nephrology 2021; 26: 312-8.
2.
Zhuang WZ, Lin YH, Su LJ, et al. Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications. J Biomed Sci 2021; 28: 28.
3.
Camarata T, Howard A, Elsey RM, et al. Postembryonic nephrogenesis and persistence of Six2-expressing nephron progenitor cells in the reptilian kidney. PLoS One 2016; 11: e0153422.
4.
Chaney A. A review for the practicing clinician: hepatorenal syndrome, a form of acute kidney injury, in patients with cirrhosis. Clin Exp Gastroenterol 2021; 14: 385-96.
5.
Gonsalez SR, Cortês AL, da Silva RC, Lowe J, Prieto MC, da Silva LL. Acute kidney injury overview: from basic findings to new prevention and therapy strategies. Pharmacol Ther 2019; 200: 1-12.
6.
Makris K, Spanou L. Acute kidney injury: definition, pathophysiology and clinical phenotypes. Clin Biochem Rev 2016; 37: 85-98.
7.
Zhao GJ, Xu C, Ying JC, et al. Association between furosemide administration and outcomes in critically ill patients with acute kidney injury. Crit Care 2020; 24: 75.
8.
Chen W, Wang F, Zhao Y, Zhang L, Chen Z, Dai M. Efficacy and safety of furosemide for prevention of intradialytic hypotension in haemodialysis patients: protocol for a multicentre randomised controlled trial. BMJ Open 2021; 11: e048015.
9.
Mohr A, Chu T, Clarkson CT, Brooke GN, Teif VB, Zwacka RM. Fas-threshold signalling in MSCs promotes pancreatic cancer progression and metastasis. Cancer Lett 2021; 519: 63-77.
10.
Bochon B, Kozubska M, Surygała G, et al. Mesenchymal stem cells-potential applications in kidney diseases. Int J Mol Sci 2019; 20: 2462.
11.
Wang Y, Shan SK, Guo B, et al. The multi-therapeutic role of MSCs in diabetic nephropathy. Front Endocrinol 2021; 12: 671566.
12.
Cao JY, Wang B, Tang TT, et al. Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury. Theranostics 2021; 11: 5248-66.
13.
Monsel A, Zhu YG, Gennai S, Hao Q, Liu J, Lee JW. Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells. Anesthesiology 2014; 121: 1099-121.
14.
Oliva J. Therapeutic properties of mesenchymal stem cell on organ ischemia-reperfusion injury. Int J Mol Sci 2019; 20: 5511.
15.
Wang P, Cui,Y, Wang J, et al. Mesenchymal stem cells protect against acetaminophen hepatotoxicity by secreting regenerative cytokine hepatocyte growth factor. Stem Cell Res Ther 2022; 13: 94.
16.
Xu J, Wang X, Chen J, et al. Embryonic stem cell-derived mesenchymal stem cells promote colon epithelial integrity and regeneration by elevating circulating IGF-1 in colitis mice. Theranostics 2020; 10: 12204-22.
17.
Selim RE, Ahmed HH, Abd-Allah SH, et al. Mesenchymal stem cells: a promising therapeutic tool for acute kidney injury. Appl Biochem Biotechnol 2019; 189: 284-304.
18.
Junn E, Han SH, Im JY, et al. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 2000; 164: 6287-95.
19.
Saxena G, Chen J, Shalev A. Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. J Biol Chem 2010; 285: 3997-4005.
20.
Kawai Y, Nakao T, Kunimura N, Kohda Y, Gemba M. Relationship of intracellular calcium and oxygen radicals to Cisplatin-related renal cell injury. J Pharm Sci 2006; 100: 65-72.
21.
Liu H, McTaggart SJ, Johnson DW, Gobe GC. Original article anti-oxidant pathways are stimulated by mesenchymal stromal cells in renal repair after ischemic injury. Cytotherapy 2012; 14: 162-72.
22.
Hu ZB, Wang LS, Cui CP, et al. Stem cell clinical application safety assessment report. Chin Med Biotechnol 2013; 8: 349-61.
23.
Song K, Huang M, Shi Q, Du T, Cao Y. Cultivation and identification of rat bone marrow-derived mesenchymal stem cells. Mol Med Rep 2014; 10: 755-60.
24.
Ashour RH, Saad MA, Sobh MA, et al. Comparative study of allogenic and xenogeneic mesenchymal stem cells on cisplatin-induced acute kidney injury in Sprague-Dawley rats. Stem Cell Res Ther 2016; 7: 126.
25.
Prieto-García L, Vicente-Vicente L, Blanco-Gozalo V, et al. Pathophysiological mechanisms underlying a rat model of triple whammy acute kidney injury. Labor Investig 2020; 100: 1455-64.
26.
Yao W, Hu Q, Ma Y, et al. Human adipose-derived mesenchymal stem cells repair cisplatin-induced acute kidney injury through antiapoptotic pathways. Exp Ther Med 2015; 10: 468-76.
27.
Yuan JS, Reed A, Chen F, Stewart CN. Statistical analysis of real-time PCR data. BMC Bioinformatics 2006; 7: 85.
28.
Downie T. Theory and practice of histological techniques edited by J.D. Bancroft & A. Stevens, Churchill Livingstone, Edinburgh, 740 pages, £55.00. Histopathology 1990; 17: 386.
29.
Gosselin EJ, Cate CC, Pettengill OS, Sorenson GD, Immunocytochemistry: its evolution and criteria for its application in the study of epon-embedded cells and tissue. Am J Anat 1986; 175: 135-60.
30.
Rota C, Morigi M, Imberti B. Stem cell therapies in kidney diseases: progress and challenges. Int J Mol Sci 2019; 20: 2790.
31.
Lee PW, Wu BS, Yang CY, Lee OK. Molecular mechanisms of mesenchymal stem cell-based therapy in acute kidney injury. Int J Mol Sci 2021; 22: 11406.
32.
Ibrahim SM, Fayez AM, Maher A. Mesenchymal stromal cells suppress hepatic fibrosis via modulating the expression of fibronectin and integrin and inhibiting DNA fragmentation in rats. Arch Med Sci. DOI: https://doi.org/10.5114/aoms/1....
33.
Wong CY. Current advances of stem cell-based therapy for kidney diseases. World J Stem Cells 2021; 13: 914-33.
34.
Xu S, De Becker A, Van Camp B, Vanderkerken K, Van Riet I. An improved harvest and in vitro expansion protocol for murine bone marrow-derived mesenchymal stem cells. J Biomed Biotechnol 2010; 2010: 105940.
35.
Morigi M, Imberti B, Zoja C, et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004; 15: 1794-804.
36.
Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 7: 994-1007.
37.
Kawai Y, Taniuchi S, Okahara S, Nakamura M, Gemba M. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bulletin 2005; 28: 1385-8.
38.
Ni J, Jiang H, Wang F, Zhang L, Sha D, Wang J. Effect of continuous furosemide infusion on outcome of acute kidney injury. Pakistan J Med Sci 2019; 35: 754-57.
39.
Bancu I, Navarro Díaz M, Serra A, et al. Low insulin-like growth factor-1 level in obesity nephropathy: a new risk factor? PLoS One 2016; 11: e0154451.
40.
Qi S, Wu D. Bone marrow-derived mesenchymal stem cells protect against cisplatin-induced acute kidney injury in rats by inhibiting cell apoptosis. Int J Mol Med 2013; 32: 1262-72.
41.
Bucher M, Taeger K.. Endothelin-receptor gene-expression in rat endotoxemia. Intensive Care Med 2002; 28: 642-7.
42.
Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 2009; 86: 396-402.
43.
Bucher M, Kees F, Taeger K, Kurtz A. Cytokines down-regulate alpha1-adrenergic receptor expression during endotoxemia. Crit Care Med 2003; 31: 566-71.
44.
Sun L, Kanwar YS. Relevance of TNF- in the context of other inflammatory cytokines in the progression of diabetic nephropathy. Kidney Int 2015; 88: 662-5.
45.
Ma W, Li C. Enhancing postmenopausal osteoporosis: a study of KLF2 transcription factor secretion and PI3K-Akt signaling pathway activation by PIK3CA in bone marrow mesenchymal stem cells. Arch Med Sci 2024; 20: 918-37.
46.
Chen L, Xiang E, Li C, et al. Umbilical cord-derived mesenchymal stem cells ameliorate nephrocyte injury and proteinuria in a diabetic nephropathy rat model. J Diabetes Res 2020; 2020: 8035853.
47.
Woodell-May JE, Sommerfeld SD. Role of inflammation and the immune system in the progression of osteoarthritis. J Orthop Res 2020; 38: 253-7.
48.
Orecchioni M, Ghosheh Y, Pramod AB, Ley K. Macrophage polarization: different gene signatures in M1(Lps+) vs. classically and M2(LPS-) vs. Alternatively activated macrophages. Front Immunol 2019; 10: 1084.
49.
Liu Y, Yin G, Surapisitchat J, Berk BC, Min W. Laminar flow inhibits TNF-induced ASK1 activation by preventing dissociation of ASK1 from its inhibitor 14-3-3. J Clin Invest 2001; 107: 917-23.
50.
Favero M, Belluzzi E, Trisolino G, et al. Inflammatory molecules produced by meniscus and synovium in early and end-stage osteoarthritis: a coculture study. J Cell Physiol 2019; 234: 11176-87.
51.
Kariya T, Nishimura H, Mizuno M, et al. TGF-1-VEGF-A pathway induces neoangiogenesis with peritoneal fibrosis in patients undergoing peritoneal dialysis. Am J Physiol Renal Physiol 2018; 314: F167-80.
52.
Ibrahim KA, Abdelgaid HA, El-Desouky MA, Fahmi A, Abdel-Daim M. Linseed ameliorates renal apoptosis in rat fetuses induced by single or combined exposure to diesel nanoparticles or fenitrothion by inhibiting transcriptional activation of p21/p53 and caspase-3/9 through pro-oxidant stimulus. Environm Toxicol 2021; 36: 958-74.
53.
Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci 2017; 13: 851-63.
54.
Bryniarski P, Nazimek K, Marcinkiewicz J. Anti-Inflammatory activities of captopril and diuretics on macrophage activity in mouse humoral immune response. Int J Mol Sci 2021; 22: 11374.
55.
Lee HJ, Oh SH, Jang HW, et al. Long-term effects of bone marrow-derived mesenchymal stem cells in dextran sulfate sodium-induced murine chronic colitis. Gut Liver 2016; 10: 412-9.
56.
Liu Y, Fang J. Mesenchymal stem cells as therapeutic agents and novel carriers for the delivery of candidate genes in acute kidney injury. Stem Cells Int 2020; 2020: 8875554.
57.
Nie WB, Zhang D, Wang LS. Growth factor gene-modified mesenchymal stem cells in tissue regeneration. Drug Design Develop Ther 2020; 14: 1241-56.
58.
Calcat-i-Cervera S, Sanz-Nogués C, O’Brien T. When origin matters: properties of mesenchymal stromal cells from different sources for clinical translation in kidney disease. Front Med 2021; 8: 728496.
59.
Li T, Zhu J, Ma K, et al. Autologous bone marrow-derived mesenchymal stem cell transplantation promotes liver regeneration after portal vein embolization in cirrhotic rats. J Surg Res 2013; 184: 1161-73.
60.
Aravindan N, Shaw A. Effect of furosemide infusion on renal hemodynamics and angiogenesis gene expression in acute renal ischemia/reperfusion. Renal Fail 2006; 28: 25-35.
61.
Jia X, Pan J, Li X, et al. Bone marrow mesenchymal stromal cells ameliorate angiogenesis and renal damage via promoting PI3k-Akt signaling pathway activation in vivo. Cytotherapy 2016; 18: 838-45.
62.
Tögel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289: F31-42.
63.
Najafian B, Alpers CE, Fogo AB. Pathology of human diabetic nephropathy. Contrib Nephrol 2011; 170: 36-47.
64.
Andrade-Silva M, Cenedeze MA, Perandini LA, et al. TLR2 and TLR4 play opposite role in autophagy associated with cisplatin-induced acute kidney injury. Clin Sci 2018; 132: 1725-39.
65.
Qian H, Yang H, Xu W, et al. Bone marrow mesenchymal stem cells ameliorate rat acute renal failure by differentiation into renal tubular epithelial-like cells. Int J Mol Med 2008; 22: 325-32.
66.
Wu HJ, Yiu WH, Li RX, et al. Mesenchymal stem cells modulate albumin-induced renal tubular inflammation and fibrosis. PLoS One 2014; 9: e90883.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
